Awareness of the implementation of the falsified medicines directive (fmd) among pharmaceutical companies’ executives in the european economic area (eea)

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-SAPS-041
• By: MERKS, Piotr (Collegium Medicum, Nicolaus Copernicus University in Toruń, Department of Pharmaceutical Technology, Faculty of Pharmacy, Bydgoszcz, Poland)
• Co-author(s): Urszula Włodarczak Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
  Damian Świeczkowski First Department of Cardiology, Medical University of Gdansk, Poland , Gdansk, Poland
  Urszula Religioni Collegium of Socio-Economics, Warsaw School of Economics, Warsaw, Poland
  Milosz Jaguszewski First Department of Cardiology, Medical University of Gdansk, Poland, Gdansk, Poland
  Jerzy Krysinski Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland
  Piotr Merks
  
• Abstract:

  Background

  FMD is a response of the European Union to the increasing number of falsified medicines present in the legal supply chain in the Member States of the Community. Effective implementation of the new regulation will depend on, among others, effective cooperation of all parties involved in the distribution of medicinal products including the

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login